LEMTRADA (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).
LEMTRADA (alemtuzumab) is a prescription medication developed by Sanofi Genzyme, specifically designed for adults with relapsing forms of multiple sclerosis (MS). It is generally prescribed when two or more MS medicines have not yielded sufficient results.
Patients undergoing treatment with LEMTRADA must follow strict safety protocols and monitoring due to the potential for serious side effects. Comprehensive patient guides, safety instructions, and REMS (Risk Evaluation and Mitigation Strategy) documentation are vital for those undergoing this treatment.
နောက်ဆုံးရလက်စွဲစာအုပ်များ manuals+ ဤအမှတ်တံဆိပ်အတွက် ရွေးချယ်ထားသည်။
လက်စွဲစာအုပ်များ၊ မှတ်ပုံတင်ခြင်းနှင့် ဤအမှတ်တံဆိပ်အတွက် ပံ့ပိုးကူညီမှုဆိုင်ရာ ဘုံမေးခွန်းများ။
LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS) in adults who have tried 2 or more MS medicines that have not worked well enough.
No. LEMTRADA is only available at a certified healthcare facility, clinic, or hospital. It is not a medicine you give yourself at home due to serious risks and required monitoring.
Patient guides and crucial safety information can be found on the official LEMTRADA website, within our manual repository, or obtained directly from your healthcare provider.
REMS (Risk Evaluation and Mitigation Strategy) is an FDA-required strategy to manage serious risks associated with LEMTRADA, ensuring prescribers and patients are fully informed of safety protocols.